In recent years, the number of observational reports published in the medical field has exploded. Several reasons may explain this exponential and novel research trend. One is the need to know whether and how the evidence-based recommended treatments are incorporated. In chronic diseases requiring long-term therapy, such as chronic heart failure (CHF), the compliance with recommended treatments is usually low, and frequently the drug doses taken are far below the recommended targets. The current widespread phenomenon of 'underdosing' might be related to non-adherence of both physician (in prescribing) and patient (in taking the prescribed drugs). On the other hand, the drug doses recommended in the current guidelines on CHF are those pre-defined as targets in placebocontrolled trials conducted in the now-remote past and subsequently systematically confirmed in guidelines as 'optimal medical therapy' in spite of evidence of an increasingly diverging clinical practice. Of note, as pointed out recently, 1 also in landmark trials, for instance those testing beta-blockers (BBs) in CHF, a substantial portion of patients (ranging from 22% to 53% could not reach the protocol-defined target doses in spite of forced titration. Information about effectiveness of other doses, either lower or higher, seldom is available. Most effective drugs in CHF have many pharmacological effects (some desirable, some not). We do not know the precise dose at which the drug exerts each of its effects maximally, or the relative contribution of each pharmacological effect to the net clinical effect of the drug. Thus, we do not truly know the 'optimal dose' for any individual patient. Moreover, as each new therapy is added to the existing list for any condition, we have no information about the continuing benefit of therapies tested before the more recent additions. Perhaps the presently recommended target doses might best be considered as thresholds beyond which drugs have not been tested, rather than as targets that must be achieved. The 'stack concept', incorporated as the standard of heart failure (HF) optimal pharmacological medical therapy, might be reconsidered, and new risk models or biomarkers should be sought to better target the available therapy according to the individual clinical conditions, which fluctuate during the evolution of HF and co-existing morbidities. 3 Actually, in hypertension, diabetes, and dyslipidaemia, the drug dosing is based on target effect on biomarkers rather than on target dose. The present issue of the journal reports a multinational study aimed to investigate 'predictors, reasons, and clinical outcome' of patients who after an acute or worsening episode of HF underwent a 3-month programme of 'encouraged up-titration' of angiotensinconverting-enzyme inhibitors (ACE-Is)/angiotensin II receptor blockers (ARBs) and/or BBs, and then were followed for 2 years The main results of the reported analyses were: first, although encouraged, very few patients reached the recommended doses of ACE-Is/ARBs (22%) and even fewer reached the target dose of BB (12%); secondly, reaching <50% of the recommended dose of ACE-Is/ARBs and BBs was associated with a worse outcome in terms of survival and HF hospitalization. 4 The proportion of patients achieving the recommended target doses in this study is one of the lowest reported in the literature so far. To develop the most important aim of this study, namely the reasons why the target drug doses were not reached by most patients, the authors classified patients into three groups: (i) those reaching the recommended dose; (ii) those not reaching the recommended dose because of symptoms, side effects, or non-cardiac organ dysfunction (namely drug tolerability); and (iii) those not reaching the recommended dose because of other/unknown/not specified reasons. Unfortunately, the last category included approximately half of patients for ACE-Is/ARBs and two-thirds of the population for BBs, in fact precluding the chance to answer this essential question thoroughly. Several reasons may lie behind the non-prescription or below-target doses of drugs. A recent analysis of a large European Society of Cardiology (ESC) registry in CHF in which the reasons for low dosing were specifically investigated revealed an overall significant rate of inappropriateness, but definitely lower than that found in the present investigation 5 ( Figure 1) . In placebo-controlled trials, it has been clearly shown that non-adherence, either with the study drug or with placebo, is a strong marker of poor outcome per se, which may account for 40% of the difference in hard outcomes between adherers and non-adherers to placebo. 6 Accordingly, caution is necessary in drawing conclusions on drug effectiveness from registry data. Also the probability of successful drug up-titration may be biased due to baseline differences among patients. The authors used several methods for correction to minimize this bias: (i) a propensity score matching; (ii) a double robust estimation analysis; (iii) inverse probability weighting with the probability to reach the recommended dose; and (iv) a multivariate model with ACE-Is/ARBs and BBs as covariate. The results confirmed that reaching <50% of the recommended doses of both ACE-Is/ARBs and BBs is associated with significantly poorer survival. A major issue in clinical research, especially in the observational domain, concerns the representativeness of the population enrolled in a study. This involves several aspects of the study design, including the size of the population, the setting of enrolment, and the criteria for selection of those enrolled (or non-selection). 7 The patients included in the study we are commenting on had a demographic profile similar to that usually seen in randomized controlled trials, namely mean age 68 years, 75% males. The demography-age and gender, strictly interlinked-is not a marginal issue in observational studies.
One of the successes in the prevention of HF is the increasing age of the patients who present with HF, with the relative increase in the burden of co-morbidities. 8, 9 This incoming patient phenotype shifts the present CHF profile further away from that of the patients included in the reference trials, and this may affect the use of evidence-based therapies. However, the trials performed by cardiologists in cardiology settings are not very sensitive to this epidemiological evolution. As the present study confirms, the population enrolled in both randomized and observational trials performed in the cardiology setting unrealistically maintain a mean age of 65 years (or less) with a male:female ratio near 3:1, fewer co-morbidities, and a much better outcome than that recorded in administrative databases. 10 The 2100 patients analysed in the present study were enrolled in 69 hospitals from 11 European countries. The number of patients included in each centre varied widely, between 1 and 157, with a median of 24 patients per centre. In a creditable attempt to reach a clinical practice representativeness, the enrolling centres were selected in each country taking into account the hospital type and complexity; however, with national networks averaging 6 centres, national or even macroregional representativeness is hard to achieve. For the same reason, cross-county or inter-regional analyses seem rather precarious. A survey performed by the ESC across the European national cardiac societies showed that there are 'significant within-and cross-country variations and inequalities in the financing, organization, access, delivery, quality, and effectiveness of cardiac care'. 11 Recently the ESC and the Organization for Economic Cooperation and Development (OECD) collaborated in an observational study aimed to identify clinical variables and health system characteristics associated with incomplete guideline application in the drug treatment of patients with CHF, across 15 European countries. 12 Patientlevel data were derived from the ESC Heart Failure Long-Term Registry, and country-level data were derived from OECD's Health System Characteristics Survey. The analyses showed that countries with an easier access to medical care, a more structured primary care system, better resourcing, and quality programmes have greater levels of appropriateness of prescription of drug treatment for CHF than countries without these characteristics. However, a long list of acknowledged limitations was discussed in this report. In the study by Ouwerkerk et al., 4 country differences turned out to be independent predictors of drug up-titration success, but it cannot be ruled out that the reasons for this were differences in the number of patients/ country enrolled or type of enrolling centres in each country rather than true regional variations in drug dosing. The limitations of the study briefly discussed above are substantially acknowledged by the authors, and represent the array of difficulties encountered by any group of investigators, including outstanding investigators such as those who authored this paper, in organizing vast international studies, based on a freshly created voluntary centre network, with scarce economic and personnel resources, no systematic auditing, and not supported by institutional databases.
However, many things are changing across the world. The current acceleration in the development and spread of new technologiesespecially Information Technology (IT)-characterizes the present time, with globalization of communication and knowledge. The incorporation of IT into the routine clinical activity of healthcare systems, generating a potentially universal Electronic Health Recording (EHR) network, sharable across countries, is now producing big data, collected day by day, to be interpreted and used by both scientists and public health authorities for a pragmatic, evidence-based public health management and governance. High-quality observational clinical research will serve as a platform for generating a new era of 'evidence-based public health policies' and 'learning Health Systems'.
